Emergent BioSolutions Inc., a leading public health company that delivers protective and life-saving solutions to communities across the world, has completed a strategic financial investment into Swiss Rockets, the parent company of Rocketvax. The funds will be used to support research, infrastructure development, and the expansion of Swiss Rockets’ portfolio..

领先的公共健康公司Emergent BioSolutions Inc.为全球各地的社区提供保护性和挽救生命的解决方案，已完成对Rocketvax母公司Swiss Rockets的战略性金融投资。这笔资金将用于支持研究、基础设施开发以及Swiss Rockets产品组合的扩展。

Rocketvax Ltd

火箭疫苗有限公司

one of Switzerland’s next-generation vaccine companies and a member of the

瑞士下一代疫苗公司之一，也是

Swiss Rockets Ltd

瑞士火箭有限公司

family of companies. One of Rocketvax’s leading

公司家族。罗克特瓦克斯的领先企业之一

candidates

候选人

is a live-attenuated nasal spray SARS-CoV-2 vaccine, which has demonstrated superior efficacy compared to mRNA COVID-19 vaccines in animal studies. Live-attenuated vaccines mimic natural infections more closely, often providing stronger and longer-lasting immunity by stimulating a broader immune response, including mucosal immunity, which is crucial for respiratory infections..

是一种减毒活疫苗鼻喷式SARS-CoV-2疫苗，在动物研究中显示出比mRNA新冠疫苗更优的效力。减毒活疫苗更接近自然感染，通常通过激发更广泛的免疫反应（包括对呼吸道感染至关重要的黏膜免疫）提供更强、更持久的免疫力。

The company has entered an agreement with

公司已经签署了一项协议

Emergent BioSolutions

新兴生物解决方案公司

for strategic investment into Swiss Rockets to support research, infrastructure development, and the expansion of Swiss Rockets’ portfolio. A leading public health company, Emergent has been delivering protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies for over 25 years..

用于对瑞士火箭公司进行战略投资，以支持研究、基础设施开发以及瑞士火箭公司产品组合的扩展。作为一家领先的公共卫生公司，Emergent在过去的25年中一直为天花、猴痘、肉毒中毒、埃博拉、炭疽和阿片类药物过量等健康威胁提供防护和挽救生命的解决方案。

In addition to the investment, the parties intend to form a strategic partnership whereby Emergent would lead the U.S. manufacturing and commercialization efforts for four of Rocketvax’s pipeline candidates for infectious diseases, cancer, and autoimmune disorders. For one of these pipeline candidates, Rocketvax has already signed a letter of intent with the U.S.

除了投资外，双方还打算建立战略合作伙伴关系，根据该协议，Emergent将负责领导Rocketvax四个传染病、癌症和自身免疫疾病候选药物在美国的生产和商业化工作。对于其中一个候选药物，Rocketvax已与美国签署了一份意向书。

National Institutes of Health (NIH). The .

美国国立卫生研究院 (NIH)。

Rocketvax / NIH collaboration

Rocketvax / NIH 合作

is part of the Project NextGen initiative and will support a clinical trial investigating a next generation vaccine using Rocketvax Ltd’s proprietary technology.

是 Project NextGen 计划的一部分，将支持一项使用 Rocketvax Ltd. 专有技术的下一代疫苗的临床试验。

Joe Papa, President and CEO of Emergent, commented: “We are excited to partner with Rocketvax to accelerate the development of innovative products that address significant public health challenges. As Rocketvax is poised to progress its pipeline, we will stand ready to leverage our unique capabilities to ultimately bring these solutions to patients and communities in need.

Emergent公司总裁兼首席执行官乔·帕帕评论道：“我们很高兴与Rocketvax合作，加速开发应对重大公共卫生挑战的创新产品。随着Rocketvax准备推进其研发管线，我们将随时准备利用我们的独特能力，最终将这些解决方案带给有需要的患者和社区。”

These four projects directly support Emergent’s strategic focus on growth and turnaround as part of our multi-year transformation plan.”.

这四个项目直接支持了Emergent关于增长和转型的战略重点，是我们多年转型计划的一部分。

Dr. Vladimir Cmiljanovic, CEO of Rocketvax Ltd, added: “This collaboration is a game-changer for Rocketvax and the broader biotech industry. By partnering with Emergent BioSolutions, we are combining cutting-edge vaccine innovation with world-class production and regulatory expertise. This joint venture not only accelerates the development of next-generation vaccines but also paves the way for groundbreaking advancements in global healthcare.

Rocketvax Ltd首席执行官弗拉基米尔·切尔米亚诺维奇博士补充说：“这次合作对Rocketvax及整个生物技术行业而言都是一个改变格局的举措。通过与Emergent BioSolutions合作，我们将尖端的疫苗创新与世界级的生产和监管专业知识相结合。这一合资企业不仅加速了下一代疫苗的开发，还为全球医疗保健领域的突破性进展铺平了道路。”

Our shared vision is to revolutionize disease prevention and immunotherapy, bringing life-saving solutions to millions worldwide. This collaboration is a major milestone for Rocketvax. By joining forces with Emergent, we can leverage their world-class production capabilities to deliver next-generation vaccines that have the potential to transform disease prevention and immunotherapy.”.

我们的共同愿景是革新疾病预防和免疫疗法，为全球数百万人带来拯救生命的解决方案。此次合作是Rocketvax的一个重要里程碑。通过与Emergent联手，我们可以利用其世界级的生产能力，交付有可能改变疾病预防和免疫疗法的下一代疫苗。"

(Press release/RAN)

（新闻稿/随机接入网络）

Image by Freepik

图片来自Freepik

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送